Cathepsin S inhibition lowers blood glucose levels in mice

Diabetologia

Volumn 57, Issue 8, 2014, Pages 1674-1683

  Lafarge, Jean Charles ^a,b,c,d   Pini, Maria ^a,b,c,d   Pelloux, Véronique ^a,b,c,d   Orasanu, Gabriela ^e   Hartmann, Guido ^f   Venteclef, Nicolas ^a,b,c,d   Sulpice, Thierry ^g   Shi, Guo Ping ^e   Clément, Karine ^a,b,c,d,h   Guerre Millo, Michèle ^a,b,c,d  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HARVARD MEDICAL SCHOOL   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g Physiogenex SAS   (France)

^h Center of Research on Human Nutrition Ile de France   (France)

Author keywords

Cathepsin inhibitors; Glucose homeostasis; Hepatic glucose production; Obesity; Type 2 diabetes

Indexed keywords

ADIPONECTIN; CARBOHYDRATE; CATHEPSIN S INHIBITOR; GLUCOSE; INSULIN; LEPTIN; LIPID; CATHEPSIN; CATHEPSIN S; GLUCOSE BLOOD LEVEL;

ADIPOSE TISSUE; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET; DNA DAMAGE; DOWN REGULATION; EMBRYO; ENERGY EXPENDITURE; ENERGY RESOURCE; ENZYME INHIBITION; FAT INTAKE; FAT MASS; FEMALE; FOOD INTAKE; FUNCTIONAL STATUS; GENE EXPRESSION; GENOTYPE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IMMUNE RESPONSE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; LIPID HOMEOSTASIS; LIPID STORAGE; LIVER; LIVER METABOLISM; MALE; MITOCHONDRIAL GENE; MITOCHONDRIAL RESPIRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY CHAIN; SPLEEN; STRESS; UPREGULATION; WEIGHT GAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; INSULIN RESISTANCE; KNOCKOUT MOUSE; METABOLISM; OXYGEN CONSUMPTION; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; CATHEPSINS; DIET, HIGH-FAT; INSULIN; INSULIN RESISTANCE; MICE; MICE, KNOCKOUT; OBESITY; OXYGEN CONSUMPTION;

EID: 84904726605     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3280-2     Document Type: Article

References (46)

1. Taleb S, Lacasa D, Bastard JP et al (2005) Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J 19:1540-1542 (Pubitemid 41279024)
2. Lecaille F, Kaleta J, Bromme D (2002) Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 102:4459-4488
3. Reiser J, Adair B, Reinheckel T (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120:3421-3431
4. Taleb S, Cancello R, Poitou C et al (2006) Weight loss reduces adipose tissue cathepsin S and its circulating levels inmorbidly obese women. J Clin Endocrinol Metab 91:1042-1047 (Pubitemid 43357778)
5. Naour N, Rouault C, Fellahi S et al (2010) Cathepsins in human obesity: changes in energy balance predominantly affect cathepsin s in adipose tissue and in circulation. J Clin Endocrinol Metab 95:1861-1868
6. Riese RJ, Wolf PR, Bromme D et al (1996) Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4:357-366 (Pubitemid 26174051)
7. Shi GP, Villadangos JA, Dranoff G et al (1999) Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10:197-206 (Pubitemid 29115625)
8. Nakagawa TY, Brissette WH, Lira PD et al (1999) Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10:207-217 (Pubitemid 29115626)
9. Saegusa K, Ishimaru N, Yanagi K et al (2002) Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 110:361-369 (Pubitemid 34847968)
10. Palermo C, Joyce JA (2008) Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29:22-28
11. Lee-Dutra A, Wiener DK, Sun S (2011) Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat 21:311-337
12. Baugh M, Black D, Westwood P et al (2011) Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 36:201-209
13. Deschamps K, Cromlish W, Weicker S et al (2011) Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma. Am J Respir Cell Mol Biol 45:81-87
14. Wang B, Sun J, Kitamoto S et al (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281:6020-6029 (Pubitemid 43847703)
15. Burden RE, Gormley JA, Jaquin TJ et al (2009) Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res 15:6042-6051
16. Ward C, Kuehn D, Burden RE et al (2010) Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One 5
17. Sukhova GK, Shi GP, Simon DI et al (1998) Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102:576-583 (Pubitemid 28376160)
18. Sukhova GK, Zhang Y, Pan JH et al (2003) Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 111:897-906 (Pubitemid 37074965)
19. Rodgers KJ, Watkins DJ, Miller AL et al (2006) Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 26:851-856 (Pubitemid 43732162)
20. Jobs E, Ingelsson E, Riserus U et al (2011) Association between serum cathepsin S and mortality in older adults. JAMA 306:1113-1121
21. Liu J, Ma L, Yang J et al (2006) Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 186:411-419
22. Jobs E, Riserus U, Ingelsson E et al (2013) Serum cathepsin S is associated with decreased insulin sensitivity and the development of diabetes type 2 in a community-based cohort of elderly men. Diabetes Care 36:163-165
23. Burcelin R, Crivelli V, Dacosta A et al (2002) Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282:E834-E842 (Pubitemid 34654745)
24. Samokhin AO, Lythgo PA, Gauthier JYet al (2010) Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice. J Cardiovasc Pharmacol 56:98-105
25. Rupanagudi KV, Kulkarni OP, Lichtnekert J et al (2013) Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-203717
26. Sulpice T, Prunet-Marcassus B, Molveaux C et al (2009) An adiponectin-like molecule with antidiabetic properties. Endocrinology 150:4493-4501
27. Weir JB (1949) New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109:1-9
28. Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550 (Pubitemid 41528093)
29. Ben Sahra I, Regazzetti C, Robert G et al (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71:4366-4372
30. Mutel E, Gautier-Stein A, Abdul-Wahed A et al (2011) Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 60:3121-3131
31. Horak P, Crawford AR, Vadysirisack DD et al (2010) Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A 107:4675-4680
32. Haslam DW, James WP (2005) Obesity. Lancet 366:1197-1209 (Pubitemid 41393598)
33. Guh DP, Zhang W, Bansback N et al (2009) The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9:88
34. Yang M, Zhang Y, Pan J et al (2007) Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol 9:970-977 (Pubitemid 47190452)
35. Funicello M, Novelli M, Ragni M et al (2007) Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores. PLoS ONE 2:e683
36. Yang M, Sun J, Zhang T et al (2008) Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol 28:2202-2208
37. Hua Y, Zhang Y, Dolence J et al (2013) Cathepsin k knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction. Diabetes 62:498-509
38. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
39. Shaw RJ, Lamia KA, Vasquez D et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646 (Pubitemid 41780780)
40. He L, Sabet A, Djedjos S et al (2009) Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137:635-646
41. Mithieux G, Guignot L, Bordet JC et al (2002) Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 51:139-143 (Pubitemid 34517990)
42. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607-614 (Pubitemid 30410251)
43. Foretz M, Hebrard S, Leclerc J et al (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120:2355-2369
44. Magnusson I, Rothman DL, Katz LD et al (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90:1323-1327
45. Basu R, Barosa C, Jones J et al (2013) Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. J Clin Endocrinol Metab 98:E409-E417
46. Edgerton DS, Johnson KM, Cherrington AD (2009) Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Front Biosci (Landmark Ed) 14:1169- 1181